IR-Center Handelsblatt

Sangui BioTech International Inc.

News Detail

DGAP-News News vom 18.07.2017

Sangui BioTech International Inc.: Revenues of USD 67,000 in fiscal year 2017; Granulox license income increased by 37%

DGAP-News: Sangui BioTech International Inc. / Key word(s): Development of Sales

18.07.2017 / 13:26
The issuer is solely responsible for the content of this announcement.

Sangui BioTech:

- Revenues of USD 67,000 in fiscal year 2017;
- Granulox license income increased by 37%.

Witten, July 18, 2017

According to preliminary unaudited figures, Sangui BioTech International Inc. achieved revenues in the amount of approximately USD 67,000 from license fees in the course of its financial year 2017 (as of June 30, 2017). Due to increased revenues of the wound spray Granulox the resulting licensing income could be increased by 37% compared to the previous year. Both revenues in the first and second half of the year were significantly higher than in the corresponding prior-year periods. After a decline in sales in the third quarter as a result of the good year-end business in the second quarter, sales of Granulox rose by 58% in the fourth quarter.

While the 2016 financial year was characterized by declining sales due to a lack of comprehensive reimbursement in Germany, this trend was more than compensated for by the increase in sales in other sales areas in the financial year just ended. As a result of the reimbursement achieved in 2016 in the Netherlands and Great Britain, Granulox sales in these countries were already 20% higher than in 2016 for the period from January to June 2017. The market in Mexico continues to be very pleasing. Here, the inclusion of Granulox in the list of hospitals available products (Cuaro basico) led to increasing demand. Increasing sales are also reported from Poland: a recent study published in Poland in patients with venous ulcers supported the efforts of the Polish sales partner.

The sales partnership concluded with Zuellig AG for South-East Asia in the autumn of 2016 is developing according to plan. Thus, Granulox was presented in Thailand as part of a national wound congress. The lectures and presentation of the therapy results obtained from Thai patients were very well received and led to the first shipments to Thailand.

"We are extremely satisfied with this development, as it is within the scope of our planning and shows that our sales concept for Granulox continues to take effect. By the end of the year 2016, we will start the launch of Granulox in Malaysia, the Philippines and Singapore together with our sales partners. We are expecting approval for Granulox for Russia in December 2017 at the latest. Our Russian cooperation partners are already working very hard on the market launch today, " explains Michael Sander, Managing Director of SastoMed GmbH, to which Sangui BioTech GmbH has licensed the worldwide distribution rights for the wound spray Granulox.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: [email protected]

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

18.07.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this